Sapphire Bioscience Holding ApS: Financial statements 2019
CVR: 38599917
Source: annual report 2019, Danish Business Authority
01/01/2019 – 31/12/2019
Sapphire Bioscience Holding ApS (CVR 38599917) has filed annual accounts for 2019. In 2019, the company reported a gross profit of DKK -37,258 and a net result of DKK 22,588,488 compared with DKK 40,003,676 the year before. Equity in the 2019 report amounted to DKK 101,309,829. The solvency ratio was 99.8%. The company had 1 employee in the financial year.
- Gross Profit
- DKK -37,258
- Profit/Loss
- DKK 22,588,488
- Equity
- DKK 101,309,829
- Total Assets
- DKK 101,483,861
- Employees
- 1
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2019 | - | -37 t. | 22.6 mio. | 101.3 mio. | 1 |
| 2018 | - | -62 t. | 40 mio. | 98.5 mio. | 1 |
Official annual report
Screen every Danish company
Combine filters on financials, industry, geography, property and risk, and instantly see which companies match.
Try company screeningEvents in 2019
Sapphire Bioscience Holding ApS has published its annual report for 2018. Gross profit came to DKK -61,625, and the net result was DKK 40,003,676.
About Sapphire Bioscience Holding ApS
Sapphire Bioscience Holding ApS is a Danish company of the type Anpartsselskab based in Ballerup, founded in 2017. The company is registered under the industry Ikke-finansielle holdingselskaber. The management consists of Michel Krall Jürgens. The board consists of Harald Høegh (chair), Eirik Lauglo, Gustaf Peter Reinhold von Ehrenheim and Peter Max. The company is owned by TTJ Invest Holding ApS and Vind Industry AS. According to the 2025 annual report, the company had an average of 1 employee. In 2025, the company reported a gross profit of DKK -112,000 and a net result of DKK 3,266,000 compared with DKK 38,793,000 the year before. Equity in the 2025 report amounted to DKK 148,277,000.